Posted by Michael Wonder on 07 Dec 2018
Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
7 December 2018 - PHARMAC is seeking feedback on a multi-product proposal with Merck Sharpe & Dohme.
The proposal would list a new, once-daily presentation of raltegravir for the treatment of HIV, as well as make changes to the contractual arrangements for the currently funded presentation of raltegravir and for posaconazole.
